首页> 美国卫生研究院文献>ecancermedicalscience >Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma
【2h】

Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma

机译:罕见的鼻窦粘膜黑色素瘤病例对口服节律化疗的特殊反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Sinonasal mucosal melanoma is a rare malignancy with limited treatment options and a poor prognosis. They are usually diagnosed at an advanced stage owing to their late and nonspecific clinical presentation. Here we present a case of relapsed refractory unresectable malignant melanoma involving the right nasal cavity managed with Oral Metronomic Chemotherapy (OMCT). A 75-year-old male patient was diagnosed with unresectable malignant melanoma involving the right nasal cavity and showed radiological progression after initial management with four cycles of Dacarbazine. He was then shifted to OMCT (Cyclophosphamide, Celecoxib and Tamoxifen), as immunotherapy could not be given due to financial constraints, on which he showed approximately 40% reduction in tumour size after 6 months. This result can have important clinical implications in resource constrained settings, where the use of immunotherapy is limited by great financial burden.
机译:鼻窦粘膜黑色素瘤是一种罕见的恶性肿瘤,治疗选择有限且预后不良。由于临床表现较晚且非特异性,他们通常在晚期被诊断出来。在这里,我们介绍了一例涉及右鼻腔的复发难治性不可切除恶性黑色素瘤病例,采用口服节律化疗 (OMCT) 治疗。1 例 75 岁男性患者诊断为累及右鼻腔的不可切除恶性黑色素瘤,初始治疗 4 个周期达卡巴嗪后出现放射学进展。然后他被转移到 OMCT(环磷酰胺、塞来昔布和他莫昔芬),因为经济拮据无法给予免疫治疗,6 个月后他的肿瘤大小减少了约 40%。在资源受限的环境中,这一结果可能具有重要的临床意义,因为免疫疗法的使用受到巨大经济负担的限制。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号